<DOC>
	<DOCNO>NCT00829374</DOCNO>
	<brief_summary>The purpose study determine Dimebon safe effective patient mild moderate Alzheimer 's disease Donepezil .</brief_summary>
	<brief_title>Safety Efficacy Study Evaluating Dimebon Patients With Mild Moderate Alzheimer 's Disease Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Mildtomoderate Alzheimer 's disease ( AD ) Probable AD ( Diagnostic Statistical Manual Mental DisordersIVText Revision ( DSMIVTR ) ) MiniMental State Examination ( MMSE ) score 12 24 , inclusive Stable donepezil least 6 month Other cause dementia Major structural brain disease Unstable medical condition significant hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>clinical trial</keyword>
	<keyword>mitochondrion</keyword>
	<keyword>memory loss</keyword>
	<keyword>neurodegenerative disease</keyword>
	<keyword>dementia</keyword>
	<keyword>investigational drug</keyword>
</DOC>